^
Association details:
| Biomarker: | NRAS G13D |
|---|---|
| Cancer: | Melanoma |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + belvarafenib (RG6185) (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Antitumor activity of belvarafenib in melanoma brain metastasis and NRAS mutation melanoma models
Published date:
03/10/2021
Excerpt:
In fact, in the NRAS G13D K1735 murine melanoma cell syngeneic mice model, the combination of belvarafenib with atezolizumab (anti-PD-L1) significantly inhibited tumor growth and effectively induced infiltration of cytotoxic T-cells into tumor tissues.
